Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554863 | 1.00 | GSK3A (0.56) | GSK3AGSK3BCHKAPOLBPKM | |
| SCHEMBL18038519 | 0.89 | GSK3A (0.67) | GSK3AGSK3BCHKAPOLBPKM | |
| SCHEMBL1553221 | 0.83 | GLA (0.62) | CHKASMN1; SMN2CDK2GLA | |
| SCHEMBL1553223 | 0.83 | GLA (0.62) | CHKASMN1; SMN2CDK2GLA | |
| SCHEMBL3696100 | 0.83 | MEN1 (0.66) | SMN1; SMN2HPGDGLANPC1RAB9A | |
| SCHEMBL3696104 | 0.83 | MEN1 (0.66) | SMN1; SMN2HPGDGLANPC1RAB9A | |
| SCHEMBL1554480 | 0.82 | ROCK2 (0.45) | CDK2GLANPC1RAB9A | |
| SCHEMBL1554477 | 0.82 | ROCK2 (0.45) | CDK2GLANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL5466350 | 0.81 | MEN1 (0.64) | SMN1; SMN2HPGDGLANPC1RAB9A | |
| SCHEMBL2103929 | 0.80 | GSK3A (0.57) | GSK3AGSK3BCHKAPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | claimed |
| EP-0370498-A2 | Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-05-30 | — | — | EP | claimed |
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9982231-B2 | Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160250260-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3039126-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-1459743-B9 | Agent for prophylaxis and treatment of glaucoma | SENJU PHARMA CO (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20030096843-A1 | Preventives/remedies for kidney diseases | MITSUBISHI PHARMA CORPORATION (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1295607-A1 | ANTITUMOR EFFECT POTENTIATORS | Mitsubishi Pharma Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1177796-A1 | PREVENTIVES/REMEDIES FOR LIVER DISEASES | Mitsubishi Pharma Corporation (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1174150-A1 | PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS | Mitsubishi Pharma Corporation (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1163910-A1 | PREVENTIVES/REMEDIES FOR INTERSTITIAL PNEUMONIA AND PULMONARY FIBROSIS | Welfide Corporation (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6218410-B1 | ADMINISTERING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF A RHO KINASE INHIBITOR COMPRISING AMIDE COMPOUND FOR INHIBITING RHO KINASE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-1034793-A1 | PREVENTIVES/REMEDIES FOR GLAUCOMA | Senju Pharmaceutical Co., Ltd. (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
| EP-0370498-A2 | Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096843-A1 | Preventives/remedies for kidney diseases | RHOA, ROCK1, MMP1 | GSK3A 878/4885GSK3B 888/4885CHKA 239/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | GSK3A 979/4885GSK3B 795/4885CHKA 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.